Bulletin Boards

Mesothelioma
- Key Statistics
- Risk Factors
- Types
- Stages
- Causes
- Diagnosis
- Symptoms
- Articles
- Alerts
- Attorneys
- Contact Us


Tell a Friend about this site
Click here  


mesothelioma lawyer

Mesothelioma Treatment


Articles and Abstracts

Therapy studies:

Pleural space perfusion with cisplatin in the multimodality treatment of malignant mesothelioma: a feasibility and pharmacokinetic study.

J Thorac Cardiovasc 1999 Apr;117(4):759-65

Ratto GB, Civalleri D, Esposito M, Spessa E, Alloisio A, De Cian F, Vannozzi MO

Istituto Anatomia Chirugica and Istituto Clinica Chirurgica, University of Genoa, Istituto Nazionale per la Ricerca sul Cancro, Servizio di Farmacologica Tossicologica, Genoa, Italy.

INTRODUCTION: Malignant pleural mesothelioma is an ideal model for testing new locoregional multimodality approaches because of its aggressive local behavior.

METHODS: This study was planned to investigate the feasibility, safety, and pharmacokinetics of a multimodality therapy including an operation, pleural space perfusion (60 minutes) with cisplatin (100 mg/m2), hyperthermia (41.5 degrees C), and postoperative radiotherapy (55 Gy to chest wall incisions). The effects of the extent of resection and perfusion temperature on cisplatin pharmacokinetics were evaluated. Ten patients with epithelial or mixed, stage I or II, malignant pleural mesothelioma underwent the following procedures: group A (3 patients), pleurectomy/decortication and normothermic pleural space antineoplastic perfusion; group B (3 patients), pleurectomy/decortication and hyperthermic perfusion; and group C (4 patients), pleuropneumonectomy and hyperthermic perfusion. Operations were selectively applied depending on tumor extent. Platinum levels were serially measured by atomic absorption in systemic blood, perfusate, lung, and endothoracic fascia.

RESULTS: The overall procedure was completed in every case, without any death or toxicity. No lung damage was demonstrated after treatment. Major complications included 1 wound infection and 1 diaphragmatic prosthesis displacement. The mean peak platimum plasma levels were reached within 45 to 60 minutes after perfusion was started. Systemic drug concentrations were reached after pleurectomy/decortication that after pleuropneumonectomy (P=.006). The local tissue/perfusate ratio of platimum concentrations tended to be higher after hyperthermic perfusion rather than normothermic perfusion.

CONCLUSION: This multimodality appraoch is feasible, pharmacokinetically advantageous, and safe enough to undergo further clinical investigations.

PMID: 9689814, UI: 98354239

Click here to order or save article


Click here

 

If you have any questions regarding treatment options or your legal rights, please contact us.


 

If you have any questions regarding your legal rights,
please
contact us.

Disclaimer | Privacy Statement

 


Asbestos | Mesothelioma | Treatment | About Us
Bulletin Boards | Site Map | Home

Mesothelioma

Copyright 1997-2008 Mesothelioma Attorney Info Center
All trademarks and copyrights are the property of their respective owners.



eBay Registration | Generator | Cord Blood | Vonage Phone | Golf Impact Indicator | eloan | Pogo Game |
Yahoo Hosting | Napster | GoToMyPC | 1and1 Hosting | Vioxx Recall | Work At Home |
Free Credit Report | Find Free Credit Report | Free Credit Check | Accessory iPod